Adding LAG-3 or TIGIT ICIs to enfortumab vedotin + pembrolizumab did not improve efficacy in pts with locally advanced or ...
Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial. Casdatifan (Cas) monotherapy in ...
As a Keymaker, we know that there isn’t a skeleton key that fits every person. And because of that we work hard to design the support & programing that you, your youth & family needs. That means if ...
Results from sub-study 03A of KEYMAKER-U03, an international, open-label, rolling-arm, phase I/II umbrella trial, spotlight the promise of pembrolizumab-based regimens combined with tyrosine kinase ...
As a Keymaker, we know that there isn’t a skeleton key that fits every person. And because of that we work hard to design the support & programing that you, your youth & family needs. That means if ...
A safety trial of antibiotic fecal microbiota transplantation for esophageal and gastric cancer patients treated with immune checkpoint inhibitors (Biorich2 trial). This is an ASCO Meeting Abstract ...
Hosted on MSN
Triplet combinations of immunotherapy and targeted treatments as first-line therapy for advanced renal cell carcinoma
KEYMAKER-U03 is an international, multicenter, open-label, Phase I/II umbrella trial evaluating experimental combinations of pembrolizumab-based immunotherapy and targeted treatments for advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results